CDMO– tag –
-
China’s AsymBio Secures $184M to Dramatically Expand Biologics CDMO Capacity, Bolstering ADC Production
PharmaSource China Overview AsymBio, a Chinese biologics CDMO, secured approximately $184 million (1.2397 billion Yuan) in financing to substantially expand its manufacturing capacity, R&D capabilities, GMP manufacturing lines, and h... -
CDMOs Boost Sterile Fill-Finish and Prefilled Syringe Capacity by Over $1 Billion to Meet Biologics and GLP-1 Drug Demand
BioProcess International USA Overview Contract Manufacturing and Development Organizations (CMOs/CDMOs) are making multi-billion dollar investments, including PCI Pharma Services' global $1 billion expansion, to significantly increase st... -
Porton Advanced Secures China NMPA Commercial Manufacturing License for CGT Products, Expanding CDMO Services from Process Development to Commercialization
Contract Pharma China Overview Porton Advanced has obtained a Class C drug manufacturing license from China's National Medical Products Administration (NMPA), enabling it to provide commercial contract manufacturing services for cell and... -
Resilience and Eli Lilly Expand Strategic Partnership with $750M Investment to Boost U.S. Manufactured Medicine Supply
Resilience USA Overview Resilience and Eli Lilly and Company have expanded their strategic partnership with a significant $750 million investment aimed at increasing the supply of critical medicines manufactured in the U.S. This investme... -
Catalent Expands AAV Gene Therapy Partnership with Taysha Gene Therapies, Securing Exclusive Commercial Manufacturing for Rett Syndrome Treatment TSHA-102
Pharma Manufacturing USA Overview Taysha Gene Therapies and CDMO Catalent have expanded their strategic partnership, designating Catalent as the exclusive commercial manufacturer for TSHA-102, an AAV-based gene therapy for Rett syndrome,... -
Cell & Gene Therapy Manufacturing Faces Deepening Bottlenecks: AmplifyBio, Exothera Close; Thermo Fisher Cuts Viral Vector Jobs, but FDA Eases Regulations to Support Growth
Endpoints News Global Overview Despite cell and gene therapies becoming a commercial reality, manufacturing remains the primary bottleneck. The CDMO sector is struggling with overcapacity and underfunding, leading to closures like Amplif... -
Catalent Bolsters End-to-End CDMO Services for Autologous & Allogeneic Cell Therapies, Including iPSC Center of Excellence
Catalent USA Overview Catalent is enhancing its end-to-end CDMO manufacturing support and process development services for both autologous and allogeneic cell therapies, covering CAR-T, TCR, TIL, NK cells, and iPSC- and MSC-derived treat... -
Fujifilm Prepares for Patent Cliff with Strategic CDMO Investments; Samsung Biologics Acquires PolyPeptide for $1.8B, Entering Peptide Market
Endpoints News Global Overview The pharmaceutical industry faces a 'patent cliff' with ~$300 billion in branded drug revenues at risk from 2025-2030, driving active deals for portfolio expansion and cost efficiency. Contract Development ... -
FUJIFILM Biosciences Unveils Oceo Rover, the First On-Demand Automated Solution for Powdered Media and Buffer Hydration, Resolving Bioprocess Bottlenecks
Bioprocess Online (FUJIFILM Biosciences) Japan Overview FUJIFILM Biosciences has launched the Oceo Rover, the first on-demand automated solution for powdered media and buffer hydration. This innovative system integrates hydration and ste... -
Precision Fermentation Drives Next-Gen Food Innovation: MycoTechnology Unveils Honey Truffle Sweet Protein, All G Launches Cow-Free Lactoferrin in US
foodingredientsfirst.com / Precision Fermentation News / flavorist.com / Vivici / Microbio International Overview Precision fermentation is significantly advancing the next-generation food ingredient market. MycoTechnology announced its ...
